Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.
Epistemonikos ID: 3e6deca02eedcd9ef667cb769ca7a02c5a04b1b6
First added on: Jan 28, 2023